ImmunoCellular Therapeutics Ltd (IMUC)

1.16
0.00 (0.00)
AMEX : Health Care
Prev Close 1.16
Open 1.19
Day Low/High 1.16 / 1.19
52 Wk Low/High 0.20 / 0.64
Volume 679.00
Avg Volume 81.80K
Exchange AMEX
Shares Outstanding 3.46M
Market Cap 4.16M
EPS -7.90
Div & Yield N.A. (N.A)

Latest News

IMUC EQUITY ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving ImmunoCellular Therapeutics, Ltd. And A Lead Plaintiff Deadline Of June 30, 2017

IMUC EQUITY ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving ImmunoCellular Therapeutics, Ltd. And A Lead Plaintiff Deadline Of June 30, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased ImmunoCellular...

IMUC LOSS NOTICE: Rosen Law Firm Reminds ImmunoCellular Therapeutics, Ltd. Of Important Deadline In Class Action - IMUC

IMUC LOSS NOTICE: Rosen Law Firm Reminds ImmunoCellular Therapeutics, Ltd. Of Important Deadline In Class Action - IMUC

Rosen Law Firm, a global investor rights law firm, reminds purchasers of ImmunoCellular Therapeutics, Ltd.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of ImmunoCellular Therapeutics, Ltd. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 30, 2017 - IMUC

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of ImmunoCellular Therapeutics, Ltd. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of June 30, 2017 - IMUC

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of ImmunoCellular Therapeutics, Ltd.

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against ImmunoCellular Therapeutics, Ltd.

INVESTOR ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd.

INVESTOR ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd.

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd. - IMUC

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against ImmunoCellular Therapeutics, Ltd. - IMUC

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of ImmunoCellular Therapeutics, Ltd.

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

ImmunoCellular Therapeutics Provides Update On ICT-107 Phase 3 Glioblastoma Trial And Announces Advances In Stem-to-T-Cell Research Program

ImmunoCellular Therapeutics Provides Update On ICT-107 Phase 3 Glioblastoma Trial And Announces Advances In Stem-to-T-Cell Research Program

- ICT-107 Protocol Amendment Being Implemented in US Clinical Sites; Amended Protocol Submissions Underway in Europe and Canada.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

ImmunoCellular Therapeutics Reports Progress In Two Lead Cancer Immunotherapy Programs

ImmunoCellular Therapeutics Reports Progress In Two Lead Cancer Immunotherapy Programs

Over 100 Patients Screened in Phase 3 ICT-107 Trial in Newly Diagnosed Glioblastoma;

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.